Angiochem's ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II Trial
June 06, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - June 06, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, presented data during a...
Angiochem to Present at ASCO 2016
May 18, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - May 18, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...
Angiochem Announces End-of-Phase 2 Meeting With FDA
May 04, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - May 04, 2016) - Angiochem, a biotechnology company developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain...
Angiochem Appoints Executive Chairman and Elects New Board of Directors
April 28, 2016 07:00 ET
|
Angiochem
MONTREAL, QC--(Marketwired - April 28, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, has appointed Mr. John...
La société américaine National Brain Tumor Society remet à Angiochem le prix de l'innovation pour souligner le développement de nouveaux traitements contre le cancer de cerveau
February 15, 2011 07:00 ET
|
Angiochem Inc.
MONTRÉAL, CANADA et WATERTOWN, MASSACHUSETTS--(Marketwire - 15 fév. 2011) - Angiochem, inc., une entreprise de biotechnologie au stade clinique, et la National Brain Tumor...
Angiochem Receives Innovation Award From the National Brain Tumor Society for Advancing the Development of Novel Brain Cancer Treatments
February 15, 2011 07:00 ET
|
Angiochem Inc.
MONTREAL, CANADA, and WATERTOWN, MASSACHUSETTS--(Marketwire - Feb. 15, 2011) - Angiochem, Inc., a clinical stage biotechnology company, and the National Brain Tumor Society (NBTS), a...